Since the discovery of insulin, we have been working on improving
treatment for people living with diabetes. We continue to focus on our
core capabilities across the spectrum of the disease to meet patients'
unfulfilled needs. Some people with type 1 diabetes cannot control
their blood glucose level and consequently struggle to lead a daily
life without potentially life-threatening and disabling hypo- and
hyperglycaemic events as well as diabetes-related complications.
Type 1 diabetes is caused by the autoimmune destruction of insulin-producing beta cells. Our researchers are working on an immunometabolic combination therapy, which they believe, in the long term, can stop the immune system attacking the beta cells and stabilise the surviving beta cells.
In addition to beta cell research, we continue to investigate
insulin and other molecules for longer-acting and more efficient
treatments to help defeat diabetes.
In 2012, Novo Nordisk launched a type 1 diabetes R&D centre in
Seattle, Washington, USA as part of Novo Nordisk's Diabetes Research
Unit. The unique concept behind the centre is to combine basic
research and early proof-of-concept trials under one umbrella.
Researchers at the centre have a mandate to pursue a translational research approach to finding new antigen-based immunological and vaccine treatment advances for type 1 diabetes via both in-house and external public–private collaborations.
Every year, we conduct clinical trials in more than 50 countries. To ensure best practice, skills and knowledge in the development of therapies, we work with the world's leading academic centres and preferred industrial partners. An overview of these activities worldwide can be found on our clinical trials website.